Share Name Share Symbol Market Type Share ISIN Share Description
Accrol Group Holdings Plc LSE:ACRL London Ordinary Share GB00BZ6VT592 ORD GBP0.001
  Price Change % Change Share Price Shares Traded Last Trade
  0.45 0.96% 47.40 42,494 11:00:42
Bid Price Offer Price High Price Low Price Open Price
46.50 47.50 47.40 47.40 47.40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Household Goods & Home Construction 136.59 -2.57 -1.10 151
Last Trade Time Trade Type Trade Size Trade Price Currency
11:14:01 O 6,848 47.50 GBX

Accrol (ACRL) Latest News (1)

More Accrol News
Accrol Investors    Accrol Takeover Rumours

Accrol (ACRL) Discussions and Chat

Accrol Forums and Chat

Date Time Title Posts
22/9/202109:40*** Accrol ***885
09/12/202011:03Accrol Papers (ACRL) Manufacturers of Soft Tissue Products3
20/6/201607:24Accrol Papers (ACRL) cleans up on AIM debut1

Add a New Thread

Accrol (ACRL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Accrol trades in real-time

Accrol (ACRL) Top Chat Posts

Accrol Daily Update: Accrol Group Holdings Plc is listed in the Household Goods & Home Construction sector of the London Stock Exchange with ticker ACRL. The last closing price for Accrol was 46.95p.
Accrol Group Holdings Plc has a 4 week average price of 46p and a 12 week average price of 40p.
The 1 year high share price is 75p while the 1 year low share price is currently 40p.
There are currently 318,878,097 shares in issue and the average daily traded volume is 541,790 shares. The market capitalisation of Accrol Group Holdings Plc is £151,148,217.98.
this_is_me: The share price continues to drift steadily upwards.
haroldthegreat: Before getting too enthusiastic about panda look at comments on line re blocking pipes . Of course there might be other causes for the blockage but I remember years ago reading about the problem with another brand . As a prospective shareholder here i decided to try their product before buying the shares ,having avoided buying own brands before ,after my clinical trial i decided to change and although the share price dropped it has been compensated by the savings on andrex . After evil tipped these shares i purchased more However.his tip on France to win the Euro was rubbish ! I only put £5 on it !
masurenguy: Good to see some significant insider share buys. Should also silence the two resident trolls for awhile !
tomps2: Accrol (ACRL) full-year 2021 results presentation The full management team Dan Wright, Executive Chairman, Gareth Jenkins, CEO, Richard Newman, CFO and Graham Cox, Commercial Director give a comprehensive overview of the turnaround to date. Watch the video here: Https://www.piworld.co.uk/company-videos/accrol-acrl-full-year-2021-results-presentation/ Or listen to the podcast here: Https://piworld.podbean.com/e/accrol-acrl-full-year-2021-results-presentation/
tomps2: Accrol Group Holdings (ACRL) full-year 2021 results webinar, today (15/07/21) at 1:15pm As part of the Group’s Financial Results roadshow, Dan Wright, Executive Chairman and Gareth Jenkins, CEO will present full year results followed by Q&A. Register here: Https://www.piworld.co.uk/events/
masurenguy: Positive results statement ! "Despite the challenges of the pandemic, the Group was able to deliver on its strategic objectives. The business was successfully scaled, through the acquisition of Leicester Tissue Company and diversified via the John Dale wet wipes acquisition. The team's continued focus on operational efficiency delivered an overall improvement in reported gross margin of 580ppt to 27.7% and a tripling of initial expectations on LTC synergies. Adjusted EBITDA rose by 47% in the year to £15.6m. Despite the volatility created in the tissue market by the pandemic limiting the Group's revenue growth to 1.4% in the Period, Accrol outperformed its peers and increased its market share to 15.9% from 13.1% in FY21. Over the last 2 years the like for like sales (excluding Away from Home) have grown by 16% from £117.6m to £136.6m and market share growth for the Group has risen from 12% to 15.9%. With the business in excellent operational shape, scalable foundations for growth in place, and a strong market position, the Group is very well placed to benefit from the anticipated recovery in tissue volumes, as the effects of the pandemic unwind. The Group expects to see FY22 exit run rates to be significantly improved with the major discounters expecting uplift in tissue volumes and Accrol's recently secured additional new business has increased confidence for FY23 revenues and returns. Trading in line with forecasts in FY22 to date and the Board remains confident in the long-term prospects for Accrol"
hew: Agree, strength of negative share price reaction surprised me rather. (I've followed both the "old Co." and the current.) Seemed to me a short term revenue issue affecting whole industry but ACRL doing better than most. Good underlying improvements through the business that bode well were ignored. Suspect many longer term holders still see primarily an "income Co." and, whilst happy with the changes, have not switched mindsets to "income and growth". I'm prepared for some further costs of growth to come - strongly hinted at - and maybe some discounting of those played a part too.
thewheeliedealer: Hi all, My mate Peter @Conkers3 and myself did a ‘Twin Petes Investing’ Podcast last week and ACRL was one of the Stocks we discussed. Neither of us hold it at the moment but I recently saw the CEO do a presentation and I am very impressed by the transformation here. In this one I started discussing how I use Spreadbets to gear-up my Returns but in a low-risk way and very much treating my Spreadbet Account like normal Shares. As always we also chatted about loads of other Stocks and Ideas for research and a fair bit of educational stuff with regards to Investing and Portfolio Management. Anyway, if you use Youtube, Apple, Audioboom, Overcast, Google+ or Spotify you can find it under the 'Conkers Corner' Channel (you want Podcast TPI 46) and you can find it on Soundcloud at the link below. I hope you enjoy it and find it useful, we try to keep them light and they are totally unscripted, with the intent being that it is like you are eavesdropping on us having a chat down the local boozer. Cheers, WD @wheeliedealer hTTps://soundcloud.com/user-479955511/conkers3-wheeliedealer-47-amzn-aapl-tsla-sfor-crda-acrl-polr-spreadbetting-aqx-wpp-tmg And you can hear it on YouTube here: hTTps://www.youtube.com/watch?v=0DJ7Ansp4pc&t=4s
this_is_me: The share price has been on an upward trend for two years. Today's rise is just a continuation of that trend which has seen the share price just about triple in that time leaving me very happy. Plenty more to come in the next two years.
davebowler: Zeus; Transformational deal We believe Accrol’s acquisition of LTC represents a transformational transaction which the potential to consolidate the Group’s leading position in the private label tissue market to c.30% share. On completion of the deal, the Group’s combined customer base will be stronger and broader with a step change in capacity to further accelerate its already impressive growth which continues to outpace the market. We estimate the acquisition to be 14.2% EPS enhancing in FY22E the first full year of ownership. The core Accrol business continues to trade solidly, driving an additional upgrade to our underlying numbers today. We believe Accrol’s established platform can deliver an market capitalisation of £400m+ over the medium term. § Acquisition overview: Accrol announced the acquisition of Leicester Tissue Company (LTC) on 2nd November, supplemented by a primary placing to raise £38.5m and an open offer raising £4.1m. The enlarged group will have c.£220m of combined revenue capacity, encompassing 12 tissue and 2 facial converting lines and c390 employees. § Key benefits: LTC is an established and well invested tissue converter with an impressive financial track record (70% revenue CAGR 2017-19), which we believe speaks for itself. LTC brings four high quality tissue conversion lines all under six years old to the Group, taking combined revenue capacity to c.£220m and enabling Accrol to defer £5.0m of capex spend from FY21 into FY22. The acquisition of LTC takes the Group’s private label market share from c26% pre acquisition to c30% post acquisition. We believe Accrol has paid less than 5x LTC’s FY22E EBITDA (post £1.0m anticipated synergies), which represents an attractive price for a strategically important transaction. § Forecasts: Our revised forecasts include an upgrade to the underlying Accrol business which has traded solidly in recent months. The acquisition should be c.14.2% EPS enhancing to our FY22E EPS forecast in the first full year of ownership on what we believe are conservative assumptions. This equates to less than 5x LTC’s 12m forward EBITDA which represents an attractive price for a strategically important transaction in our view. Cost synergies of £1.0m have been identified, which we believe is conservative, with no revenue synergies currently assumed throughout our forecast period. § Investment view: In our view Accrol deserves to trade at least in line, if not at a premium to its peers given its solid growth momentum. A rerating of the shares to 16x-18x FY22E PE over the next 12 months implies a share price of 69-78p. Ultimately we believe Accrol should emerge as a £35m-£40m EBITDA business (£22.5m-£30.0m previously assumed) with minimal debt and above average growth in the ever-expanding discount sector, which we believe could equate to an equity value of c.£400m (c.122p per share) over the medium term.
Accrol share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210928 10:35:35